A pivotal, high-level joint workshop convened by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on September 25, 2026, illuminated the complex and evolving regulatory pathways for botanical drugs in both major markets. The session, held at the EMA headquarters in Amsterdam, aimed to foster greater understanding and propose avenues for streamlining the development and market access of these naturally derived medicinal products. Despite an early start that posed a challenge for North American participants, the event drew over 1,000 attendees, signaling a significant and widespread interest in the future of botanical drug regulation.
The workshop’s agenda was meticulously crafted to address the rising global demand for herbal and botanical health products, explore the distinct regulatory frameworks in the U.S. and EU, and identify potential hurdles and solutions for bringing these compounds to market. The participation of top-tier administrators from both regulatory bodies, alongside representatives from influential stakeholder organizations such as the Reagan Udall Foundation for the FDA, the Botanicals Safety Consortium, the American Botanical Council (ABC), and the American Herbal Products Association (AHPA), underscored the collaborative spirit and the critical importance of the discussions.
The Ascending Trajectory of Botanical Medicines
The day commenced with a deep dive into the burgeoning popularity and recognized importance of botanical products. Stefan Gafner, Chief Science Officer at the American Botanical Council, presented compelling data illustrating the rapid acceleration of herbal product sales in the United States. His findings highlighted a critical disparity in product integrity: botanical health products marketed under the EU’s established botanical drug framework demonstrated a significantly lower risk of adulteration compared to similar products sold as dietary supplements in the U.S., where adulteration rates remain a persistent concern. This distinction underscores the inherent strengths of a well-defined regulatory pathway for ensuring product quality and consumer safety.
Further insights into the consumer and healthcare provider perspective were offered by Jorge Batista, representing a group of community pharmacies. He detailed the integral role pharmacists play in the administration and guidance of botanical drugs within European member states, emphasizing their position as frontline dispensers of this therapeutic category. Dominique Hamerlijnck of the European Lung Foundation provided a vital consumer viewpoint, articulating the current difficulties consumers face in accessing clear, comprehensive information about botanical drugs. She noted that while crucial data, such as potential drug interactions, exists, it is often fragmented across multiple websites and buried within technical nomenclature, such as Latin binomial species names, making it overly challenging for the average patient to navigate. This lack of accessible information can lead to suboptimal therapeutic outcomes and potential safety risks.
Navigating the Labyrinth: Regulatory Frameworks and Divergent Approaches
The core of the workshop focused on the intricate regulatory structures governing botanical drugs in the U.S. and the EU. Cassandra Taylor of the FDA outlined the U.S. framework, which is firmly rooted in the Food, Drug, and Cosmetic (FD&C) Act, further elaborated through a complex web of regulations and guidance documents. This approach typically demands extensive preclinical and clinical data to establish safety and efficacy for specific therapeutic indications.
In contrast, Carmen Purdel, Chair of EMA’s Committee for Herbal Medicinal Products (HMPC), described the EU’s more "bottom-up" regulatory methodology. This system leverages a substantial body of existing safety data derived from products already on the market within the EU, often under various traditional herbal medicine designations. The EMA’s framework assesses products based on their intended market reach, distinguishing between applications for the entire EU market versus those seeking approval in select member states. This nuanced approach allows for flexibility but also introduces a degree of complexity in cross-border market access.
Case Study: FILSUVEZ and the Nuances of Approval
A crucial element of the discussion involved a detailed case study of FILSUVEZ, a drug derived from a birch extract containing a complex of birch triterpenes, used in the treatment of a rare skin disease. This particular compound has achieved approval in both the U.S. and the EU, providing a tangible example of the differing regulatory expectations.
Charles Wu of the FDA highlighted the significant emphasis placed by the U.S. agency on the rigorous characterization of the active substance. FDA’s approval process for FILSUVEZ demanded comprehensive proof that the manufacturing process could consistently yield a product with minimal batch-to-batch variation. This focus on detailed chemical profiling and manufacturing control is a hallmark of the FDA’s approach to drug approval.
Jacqueline Wiesner of the EMA’s HMPC, on the other hand, detailed the EU’s approval for FILSUVEZ. The European regulatory pathway, in this instance, required standardization to only one of the key terpenes within the birch extract, representing a less stringent requirement for compositional analysis compared to the FDA’s demands. This divergence in scientific rigor, while potentially accelerating market entry in the EU, raises questions about the comparability of safety and efficacy data generated under each system.
The Economic Chasm: Cost as a Significant Barrier
The comparative case study, while illuminating regulatory differences, did not explicitly delve into one of the most significant practical hurdles: the prohibitive cost associated with bringing botanical drugs to market in the United States. Reports suggest that the U.S. approval process can be as much as ten times more expensive than its EU counterpart. This economic disparity has demonstrably stifled innovation, with only a handful of botanical drugs receiving FDA approval over several decades. Many submissions reportedly falter due to the inability to meet the FDA’s stringent quality parameters and demonstrate the necessary manufacturing consistency.
Charting a New Course: Suggestions and Stakeholder Perspectives
The workshop culminated in a dynamic panel discussion featuring prominent figures from industry and advocacy groups, including Angela Mueller and Christelle Anquez-Traxler of the Association of the European Self-Care Industry (AESGP), Holly Johnson from AHPA, and Susan Winckler of the Reagan Udall Foundation for the FDA. The dialogue generated several forward-thinking suggestions aimed at alleviating the challenges faced by botanical drug developers.
One prominent proposal was the consideration of establishing a novel regulatory category in the U.S. that would exist between conventional pharmaceuticals and dietary supplements. This intermediary category could potentially house botanical drugs, providing a more tailored regulatory pathway than either extreme. However, Susan Winckler of the Reagan Udall Foundation cautioned that implementing such a category would necessitate an amendment to the FD&C Act, a legislative undertaking that is generally viewed as complex and unlikely in the current political climate.
Another recurring suggestion, a familiar refrain in such industry dialogues, was the call for increased targeted research and enhanced public funding to support this research. This sentiment reflects a broader understanding that robust scientific evidence is paramount for navigating regulatory approval and ensuring public confidence in botanical medicines.
Industry Watchdog’s Endorsement and Forward-Looking Remarks
Roy Upton, founder of the American Herbal Pharmacopoeia, a highly respected authority in the field, has been closely monitoring the renewed impetus for botanical drug development. His engagement is driven by a desire to identify and mitigate any potential unintended consequences that could impact herbal products marketed as supplements in the U.S. In the wake of the FDA/EMA workshop, Upton shared his considered written comments, offering a valuable stakeholder perspective.
"The workshop demonstrated growing international interest in the development and regulation of botanical medicinal products and highlighted both significant opportunities and substantial challenges," Upton observed. He elaborated that the central themes of the discussions revolved around the critical importance of safety, efficacy, quality, pharmacovigilance, real-world evidence, appropriate regulatory pathways, robust education initiatives, enhanced transparency, and fostering collaborative efforts across the industry and regulatory bodies.
Upton further emphasized the value of learning from established regulatory practices, particularly drawing upon the extensive experience accumulated within the European system over more than two decades. Simultaneously, he underscored the necessity of acknowledging and respecting the distinct statutory and regulatory environment that defines the United States. His comments reflect a balanced perspective, advocating for harmonization where possible while respecting national sovereignty in regulatory affairs.
The organizers confirmed that a recording of the session would be made available to those who were unable to attend, ensuring that the valuable insights and discussions reach a wider audience within the global botanical health community. This commitment to accessibility underscores the collaborative spirit fostered by the workshop and its potential to shape the future of botanical drug development and regulation worldwide. The convergence of regulatory expertise and stakeholder engagement signals a promising, albeit challenging, path forward for bringing the therapeutic potential of botanicals to a broader patient population.
